Format

Send to

Choose Destination
Pediatr Infect Dis J. 2017 Mar;36(3):326-332. doi: 10.1097/INF.0000000000001428.

Circulating Antibody 1 and 2 Years After Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine in Preterm Compared With Term Infants.

Author information

1
From the *Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago de Compostela and Vaccine Research Unit, Genetics, Vaccines, Infections and Pediatrics Research Group (GENVIP), Healthcare Research Institute of Santiago, Santiago de Compostela, Spain; †Department of Preventive Medicine, Poznań University of Medical Sciences, Poznań, Poland; ‡Vaccine Research, Pfizer Inc, Collegeville, Pennsylvania; §Department of Infectious Diseases, Infectious Diseases Outpatient Clinic, Kraków, Poland; ¶Department of Pediatric Infectious Diseases, Medical University of Łódź, Łódź, Poland; ‖Sección Servicio Neonatología, Hospital Infantil La Paz, Madrid, Spain; **Departamento Pediatria, Complexo Hospitalario Universitario de Vigo, Vigo, Spain; ††Pediatrics Department, Hospital Torrecardenas, Almeria, and Balmis Institute of Vaccines, Spain; ‡‡Department of Pediatric Infectious Diseases, Medical University, Wrocław, Poland; §§Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitario 12 de Octubre, Madrid, Spain; ¶¶Pediatrics Department, Vaccine Research Unit, Fundación Miguel Servet, Complejo Hospitalario de Navarra, IdiSNA, Pamplona, Spain; ‖‖Vaccine Research, Pfizer Inc, Pearl River, New York; and ***Biostatistics, PBU in Ventiv Health Clinical, LLC, Princeton, New Jersey.

Abstract

BACKGROUND:

Premature infants have lower short-term immune responses to vaccination than term infants, but patterns of antibody persistence in preterm infants over longer periods are not well established. This study assessed the persistence of antibody response to the 13-valent pneumococcal conjugate vaccine (PCV13) in formerly preterm versus term infants.

METHODS:

In total, 100 preterm and 100 term infants received PCV13 with routine vaccines at ages 2, 3, 4 and 12 months. Serotype-specific anticapsular immunoglobulin G (IgG)-binding antibodies and opsonophagocytic activity were determined 1 and 2 years after the last PCV13 dose.

RESULTS:

At 1 and 2 years after the last vaccination (toddler dose), IgG geometric mean concentrations (GMCs) for all serotypes had declined from levels measured 1 month after the toddler dose but remained above pretoddler dose levels. IgG GMCs were significantly lower in preterm than term subjects for a majority of serotypes at both follow-up time points. IgG GMCs increased in both groups for some serotypes from the 1-year to 2-year follow-up, whereas others declined. Opsonophagocytic activity results supported the IgG results.

CONCLUSIONS:

The routine (3 + 1) vaccination schedule is likely to offer long-term protection against invasive pneumococcal disease in preterm infants and should be initiated regardless of gestational age or weight at birth, without delay of the toddler dose.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01193335.

PMID:
27902652
DOI:
10.1097/INF.0000000000001428
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center